Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

m its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Quarter Ended June 30, Year Ended June 30,2011201020112010REVENUESLicense and contract

$
24,691$
74,957$
497,540$ 14,180,727Grants

131,149-977,917-Total revenues

155,840674,9571,475,45714,180,727OPERATING EXPENSES:Research and development

3,217,3853,554,52110,377,01912,293,910General and administrative

1,525,0261,374,3204,751,8244,901,203Total operating expenses

4,742,4114,928,84115,128,84317,195,113Loss from operations

(4,586,571)(4,253,884)(13,653,386)(3,014,386)OTHER INCOME (EXPENSE):Investment income

26,91621,36599,258141,635Interest expense

(4,999)(3,862)(10,606)(13,165)Decrease/(increase) in fair value of warrants

1,255,425-(2,266)-Gain on sale of securities

--119,346-Gain/(loss) on disposition of supplies and equipment

--(5,666)95,000Total other income, net

1,277,34217,503200,066223,470Loss before income taxes

(3,309,229)(4,236,381)(13,453,320)(2,
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
... on nanoimprinting techniques (NIL) is evolving at a rapid pace. ... in order to reach the market? How do we bridge ... industry? What are the tools needed for each product? ... to life science products were discussed by more than 80 ...
... Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today ... of 2012. First Quarter Financial ResultsFor ... $18.1 million compared to $20.1 million for the same period ... to $17.4 million ($0.09 per share) for the quarter ended ...
... Fla., April 19, 2012  New data presented today ... delivering inhaled nitric oxide (NO) to patients being ... ), a privately held, advanced development-stage technology company, ... System during Right Heart Catheterization (RHC) in subjects ...
Cached Biology Technology:Tackling the European market of nanoimprint lithography 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 5New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... 2010 Imagine creating novel devices with amazing and ... a droplet of particles on a surface. By ... team of Harvard researchers, in collaboration with scientists at ... the University of Houston, has developed just that. ...
... Ardipithecus ramidus a purported human ancestor ... is coming under fire from scientists who say there ... dense woodlands at the African site where the creature lived ... for open savanna habitats," says University of Utah geochemist Thure ...
... State University College of Medicine researcher has discovered a new ... that may be the cause of B-cell lymphoma. The finding ... of other types of cancer, leading to further understanding of ... Yoichi Kato, an assistant professor in the Department ...
Cached Biology News:Applied physicists create building blocks for a new class of optical circuits 2Applied physicists create building blocks for a new class of optical circuits 3Out of the woods for 'Ardi' 2Out of the woods for 'Ardi' 3Out of the woods for 'Ardi' 4Medical researcher's discovery may explain how certain cancers develop 2
... 97 Cytological Labeling Kit provides a unique ... of cellular targets, including cell-surface receptors and ... Kit contains the patented ELF 97 phosphatase ... precipitate at the site of enzymatic activity ...
... between the various commercial and lab-prepared glass ... the length and GC content of the ... protocol employed all influence the optimal hybridization ... all the different variables to consider, it ...
... Stain combo offers these benefits: ... Offers a safer and ... Eliminates risks to yourself, the environment and your ... bp to >30 kb. UltraPure Agarose is a standard ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
Biology Products: